I'm delighted to announce that PopVax (@popvax.com) has been awarded $2M by the US Biomedical Advanced Research and Development Authority (@bardagov.bsky.social) as a winner of the first stage of BARDA’s Patch Forward Prize for our seasonal influenza vaccine, along with our partner LTS. (1/12)

I've written a short piece about the potent, broadly-protective flu vaccines we're developing at PopVax to protect against both seasonal influenza strains and potential pandemic influenza such as the H5N1 strains currently circulating in cows

chronicles.popvax.com/p/potent-bro...

(thread below)

We now seek to apply our v/acc approach – vaccine accelerationism – to HCV, Strep A, and TB, three pathogens which collectively kill ~2 million people a year, and for which there are no existing effective vaccines. More in the video below: (4/4)

youtu.be/OXxo49WrODQ

Our soon-to-be open sourced COVID-19 vaccine funded by Vitalik & Balvi is designed to protect against both current & future variants of SARS-CoV-2, aligning with the goals of d/acc. It will enter a Phase I trial in the US conducted & sponsored by NIAID (@niaidnews.bsky.social) in 2025. (3/4)

Vitalik, via his biosecurity and public health organization Balvi, was the first to believe in our vision of leveraging the 10x cost & speed advantages of doing R&D in India to develop fundamentally better, broader, safer, and more transparent vaccines, and is our largest funder. (2/4)

I recently spoke at Ethereum Devcon about PopVax (@popvax.com)'s work developing novel mRNA vaccines to save 1 million lives each year, as part of a series of talks organized by Vitalik Buterin (@vitalik.ca) around his d/acc vision – defensive, differential, and decentralized accelerationism. (1/4)

PopVax (@popvax.com) is pleased to announce that NIAID (@niaidnews.bsky.social), part of the US National Institutes of Health, will conduct & sponsor the Phase I clinical trial of PopVax’s next-generation mRNA COVID-19 vaccine as part of the U.S. Government’s Project NextGen. (1/5)